Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer.

Transl Lung Cancer Res · 2025 · PMC12541879 · PMID 41132976

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a favorable trendP=0.07so close (0.05 < p ≤ 0.1)

Although PFS demonstrated a favorable trend, the difference was not statistically significant (9.7 vs. 8.3 months, P=0.07).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.